((自动化翻译由路透提供，请见免责声明 ))
12月31日 - ** 尽管治疗睡眠障碍的GLP-1药物的威胁迫在眉睫，但睡眠呼吸暂停器械制造商的股票在2024年底的表现仍将喜忧参半
** 瑞思迈 和Inspire Medical 生产用于治疗睡眠呼吸暂停的医疗设备。
** 礼来 的减肥药Zepbound本月获得批准，成为FDA批准的首个治疗睡眠障碍的药物。
** 设备生产商此前对市场担忧避而不谈，但一些分析师表示，明年的需求可能会出现中断。
** RMD股价上涨了33.54%，这是该公司股价在连续两年下跌后首次上涨，部分原因是业绩强劲，而且飞利浦 同意 (link)，在未来几年内不再在美国销售治疗睡眠呼吸暂停的新设备，因为该公司正在努力遵守与FDA达成的和解协议。
** INSP 下跌 6.9%，连续第二年亏损
** 同样拥有治疗睡眠呼吸暂停产品的 LivaNova 股价在 2024 年下跌了 10.8%，这是该公司第三年亏损。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.